Study S000768

A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

ClinicalTrials.gov record

Registration

Registration: NCT07379333
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: RECRUITING
Enrollment: 118
Start: 2026-04-13
Primary completion: 2027-11
Lead sponsor: Hanmi Pharmaceutical Company Limited
Conditions: Type 2 Diabetes
Interventions: DRUG:HM11260C; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Change in HbA1c at 36 weeks compared to baseline [baseline, 36 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.